ABVC BioPharma Inc (ABVC)
1.53
-0.06
(-3.77%)
USD |
NASDAQ |
Apr 26, 09:50
ABVC BioPharma Cash from Financing (TTM): 3.919M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 3.919M |
September 30, 2023 | 3.578M |
June 30, 2023 | 2.525M |
March 31, 2023 | 6.220M |
December 31, 2022 | 4.014M |
September 30, 2022 | 8.520M |
June 30, 2022 | 13.73M |
March 31, 2022 | 9.953M |
December 31, 2021 | 9.996M |
September 30, 2021 | 12.61M |
June 30, 2021 | 7.238M |
March 31, 2021 | 9.000M |
December 31, 2020 | 9.568M |
September 30, 2020 | 3.303M |
June 30, 2020 | 3.611M |
March 31, 2020 | 2.324M |
December 31, 2019 | 3.088M |
September 30, 2019 | 2.409M |
June 30, 2019 | 1.512M |
March 31, 2019 | 1.617M |
December 31, 2018 | 0.593M |
September 30, 2018 | |
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 |
Date | Value |
---|---|
September 30, 2017 | 1.63M |
June 30, 2017 | 1.41M |
March 31, 2017 | 3.367M |
December 31, 2016 | 2.42M |
September 30, 2016 | 2.653M |
June 30, 2016 | 2.353M |
March 31, 2016 | 0.3067M |
December 31, 2015 | 0.3034M |
September 30, 2015 | 0.00 |
June 30, 2015 | 0.00 |
March 31, 2015 | 0.00 |
December 31, 2014 | 0.00 |
September 30, 2014 | 0.00 |
June 30, 2014 | 0.00 |
March 31, 2014 | 0.00 |
December 31, 2013 | 0.00 |
September 30, 2013 | 0.025M |
June 30, 2013 | 0.0697M |
March 31, 2013 | 0.3731M |
December 31, 2012 | 0.5582M |
September 30, 2012 | 0.8763M |
June 30, 2012 | 1.132M |
March 31, 2012 | 1.228M |
December 31, 2011 | 1.872M |
September 30, 2011 | 1.701M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.512M
Minimum
Jun 2019
13.73M
Maximum
Jun 2022
6.164M
Average
4.014M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
NeuBase Therapeutics Inc | 4.254M |
Sutro Biopharma Inc | 137.55M |
Reviva Pharmaceuticals Holdings Inc | 33.17M |
Flora Growth Corp | 3.15M |
Journey Medical Corp | -4.804M |